Journal
AIDS
Volume 25, Issue 3, Pages 388-390Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/QAD.0b013e3283427e05
Keywords
-
Categories
Funding
- NIH, NIAID [K23 AI071760]
- Doris Duke Foundation
- National Institute of General Medical Sciences (NIGMS), National Institutes of Health (Bethesda, Maryland, USA) [R01GM061834]
Ask authors/readers for more resources
Some individuals have higher efavirenz plasma concentrations during rifampin-containing tuberculosis (TB) therapy, contrary to the expected induction effect of rifampin. Among HIV-infected patients without (n = 38) and with TB on rifampin-containing therapy (n = 18), we tested the hypothesis that drug-gene interaction may explain the highly variable drug interactions. Two-way analysis of variance revealed a significant interaction between CYP2B6 516G -> T polymorphism and rifampin-containing therapy, suggesting that efavirenz dose adjustment may need to be individualized on the basis of the patient's genotype.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available